Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34299259)

  • 1. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
    Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
    Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
    Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
    Fancher KM; Pappacena JJ
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):507-515. PubMed ID: 32940733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS; Ou YC; Trotman J; Opat S
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
    [No Abstract]   [Full Text] [Related]  

  • 7. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
    Benner B; Carson WE
    J Hematol Oncol; 2021 Jan; 14(1):15. PubMed ID: 33441177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Development of BTK Inhibitors: A Five-Year Update.
    Tasso B; Spallarossa A; Russo E; Brullo C
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
    Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D; Wang J; Hong J
    Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
    J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib and novel BTK inhibitors in clinical development.
    Akinleye A; Chen Y; Mukhi N; Song Y; Liu D
    J Hematol Oncol; 2013 Aug; 6():59. PubMed ID: 23958373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
    Liu N; Hoogendoorn S; van de Kar B; Kaptein A; Barf T; Driessen C; Filippov DV; van der Marel GA; van der Stelt M; Overkleeft HS
    Org Biomol Chem; 2015 May; 13(18):5147-57. PubMed ID: 25849561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.